drugset / Trial / NCT00640393

Safety and Efficacy of Combining nbUVB to Etanercept in Patients

NCT00640393

Phase 4 Completed 99 enrolled Innovaderm Research Inc. Amgen · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.

Timeline

Start
2008-04
Primary completion
2010-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications